Source-grounded facts extracted from HeartSciences Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HeartSciences Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $3,605,000 (effective 2026-01-13).
“On January 13, 2026, HeartSciences Inc. (the “Company” entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC, an institutional investor (“Streeterville”), pursuant to which Streeterville purchased from the Company an unsecured promissory note in the amount of $3,605,000”
HeartSciences Inc. incurred senior notes of $3,605,000 with Streeterville Capital, LLC at 12% per annum maturing 18 months after its issuance date.
“On January 13, 2026, HeartSciences Inc. (the “Company” entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC, an institutional investor (“Streeterville”), pursuant to which Streeterville purchased from the Company an unsecured promissory note in the amount of $3,605,000 (the “Note”)”
HeartSciences Inc. amended loan of $500,000 with Front Range Ventures LLC at 12% per annum maturing September 30, 2026.
“Loan Agreement, the No. 1 Amendment, the No. 2 Amendment, the No. 3 Amendment, the No. 4 Amendment and the No. 5 Amendment, the “Loan Agreement”), for the Company to borrow $500,000 from Front Range Ventures LLC (“FRV”) as evidenced by a secured, non-convertible promissory note, dated April 24, 2020, as amended by the Amended and Restated Secured Promissory”
HeartSciences Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“osed. As previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on March 21, 2025, the Company previously received a letter from the Staff indicating that the Company was not in compliance with the requirements of Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity (the “Minimum Stockholders’ Equity Requirement”), and the Company did not otherwise meet the alternative requirements of market value of listed securiti”
HeartSciences Inc.: Amended Bylaws to add jury trial waiver for internal entity claims, adopt ownership threshold for derivative proceedings, and clarify exclusive forum provision (effective 2025-06-27).
“On June 27, 2025, in connection with certain recent changes to the Texas Business Organizations Code (“TBOC”) and in light of Texas law, the Board of Directors of HeartSciences Inc. (the “Company”) adopted certain amendments to the Company’s Bylaws (the “Bylaws”) in order to: (i) add a new section to provide for a jury trial waiver for “internal entity claims” as defined in the TBOC; (ii) add a new section to adopt an ownership threshold requiring any shareholder or group of shareholders to hold shares of common stock sufficient to meet an ownership threshold of at least 3% of the Company’s issued and outstanding shares in order to institute or maintain a derivative proceeding; and (iii) make technical revisions to clarify the scope of the exclusive forum provision.”
HeartSciences Inc.: Filed Certificate of Designations for Series D Convertible Preferred Stock, designating 4,285,714 shares as Series D Preferred Stock, effective May 21, 2025 (effective 2025-05-21).
“On May 28, 2025, the Company was notified by the Secretary of State of the State of Texas (the “Texas Secretary of State”) that the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series D Convertible Stock (the “Certificate of Designations”) was filed with the Texas Secretary of State, effective as of May 21, 2025, designating 4,285,714 shares of the Company’s preferred stock, $0.001 par value per share, as the Company’s Series D Convertible Preferred Stock, $0.001 par value per share (the “Series D Preferred Stock”).”
HeartSciences Inc.: Certificate of Amendment to Amended and Restated Certificate of Formation to effect a 1-for-100 reverse stock split of Common Stock and Warrants (effective 2024-05-06).
“the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Formation (the “Certificate of Amendment”) with the Secretary of State of Texas to, among other things, effect on the corporate level a one-for-one hundred reverse stock split (the “Reverse Stock Split”) of the Company’s shares of common stock, $0.001 par value per share (the “Common Stock”), and also to effect a one-for-one hundred Reverse Stock Split of the Company’s warrants (the “Warrants”).”
HeartSciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).
“May 9, 2024, the Company received a staff determination from Nasdaq to delist the Company’s securities from the Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because, as of May 8, 2024, the Company’s Common Stock had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). The Company may appeal the Staff Determination to a Nasdaq Hearings Panel (the “Panel”) by filing a hearing request wit”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.